Teva Pharmaceutical Industries Ltd.'s bid to dismiss antitrust claims should be denied in a case where Mylan Pharmaceuticals Inc. alleges the company unlawfully delayed a generic version of a multiple ...
In high-income countries, more than 80% of children diagnosed with cancer will survive. Yet in some low- and middle-income ...
Teva's stock is a speculative buy with potential upside if biosimilars succeed, but risks remain high due to debt and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results